Enasidenib,Azacitidine,venetoclax
Servier,roche,abbvie
['azacitidine,(-oral azaci),(-azacitidine oral)', 'enasidenib', 'leukemia', 'beat aml', 'aza ', '+aza', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'lymphoma', 'venetoclax', 'master trial']
congress | #ash22 shares updated results from the phase ii/ib beat aml master trial where enasidenib continued to be a safe, well-tolerated therapy in patients 60 years with nd midh2 aml alone and with the risk-adaption addition of venetoclax. #leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm